基本信息
views: 1097
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and a first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma. Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD
Research Interests
Papers共 1380 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
NATURE COMMUNICATIONSno. 1 (2024)
Nature communicationsno. 1 (2024): 1367-1367
Tondre Buck,Monique A. Hartley-Brown, Yvonne A. Efebera,Carter P. Milner,Jeffrey A. Zonder,Paul G. Richardson,Taylor Salinardi,Megan S. Rice
HAEMATOLOGICAno. 6 (2024): 1882-1892
LEUKEMIA (2024)
Haematologicano. 7 (2024): 2239-2249
Oncogenepp.1-1, (2024)
Blood cancer journalno. 1 (2024): 107-107
Haematologicano. 1 (2024)
EUROPEAN JOURNAL OF HAEMATOLOGYno. 3 (2024): 402-411
Load More
Author Statistics
#Papers: 1368
#Citation: 107433
H-Index: 150
G-Index: 304
Sociability: 9
Diversity: 3
Activity: 282
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn